Incidence and risk factors of first-line haart discontinuation: is it worth choosing competing risk or standard survival approaches?

HIGHLIGHTS

• who: Momory Keita from the Inserm-Université de Toulouse III, allées Jules Guesde, Toulouse, France have published the paper: Incidence and Risk Factors of First-Line HAART Discontinuation: Is It Worth Choosing Competing Risk or Standard Survival Approaches?, in the Journal: (JOURNAL) of June/30,/2008
• how: The authors studied 1136 patients receiving Highly Active Antiretroviral Therapies (HAART) aged over 18 years from the Dat'AIDS cohort Toulouse France between January 2000 and June 2008. incidence was estimated with 1-KM and CIF estimators and risk factors with Cox and Fine-Gray models. To . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.